https://www.selleckchem.com/products/abt-199.html The presence of (1 → 3)-β-D-glucan in human plasma is a marker for fungal infections. Currently, the Limulus amebocyte lysate (LAL)-based assay is widely used for the quantification of plasma (1 → 3)-β-D-glucan. However, it has limitations in clinical use, such as an unstable supply of natural resources, complicated manufacturing process, and low-throughput of the reagents. Alternative assays exploiting specific antibodies against (1 → 3)-β-D-glucan have been developed to overcome these challenges. However, these methods are associated with low sensitivity and poorly correlate with the data obtained by the LAL-based assay. The aim of this study is to develop a novel enzyme immunoassay that is as sensitive and accurate in determining plasma (1 → 3)-β-D-glucan levels as compared to that obtained with the LAL-based assay. We generated specific monoclonal antibodies against (1 → 3)-β-D-glucan that recognizes four-unit glucose oligomers with (1 → 3)-β-D-linkages, and constructed a sandwich enzyme-linked immunosorbficiency as the LAL-based assay. This assay is characterized by good performance, stable supply of materials, and simple manufacturing process and is more suitable for the high-throughput diagnosis of fungal infections.A pervasive issue in stable isotope tracing and metabolic flux analysis is the presence of naturally occurring isotopes such as 13C. For mass isotopomer distributions (MIDs) measured by mass spectrometry, it is common practice to correct for natural occurrence of isotopes within metabolites of interest using a linear transform based on binomial distributions. The resulting corrected MIDs are often used to fit metabolic network models and infer metabolic fluxes, which implicitly assumes that corrected MIDs will yield the same flux solution as the actual observed MIDs. Although this assumption can be empirically verified in special cases by simulation studies, there seems to be no published proof of